Also, treatment of drug-susceptible TB involves several drugs, including RIF, which is a CYP2E1 inducer, thus drug-drug interactions could potentially interfere with INH metabolism or manifestation of INH-related adverse drug reactions through increased production of reactive metabolites, especially in slow acetylators (Shen et al., 2008; Yamada et al., 2009). This evidence concerns the gene CYP2E1 and tuberculosis.